scholarly journals Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep

Respirology ◽  
2018 ◽  
Vol 23 (4) ◽  
pp. 421-433
Author(s):  
Amanda J. Piper ◽  
Stephen J. Wort ◽  
Elisabetta A. Renzoni ◽  
Vasileios Kouranos
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Vascular Disease ◽  
Pulmonary Vascular Disease

The lung in autoimmune rheumatic disorders

2010 ◽  
pp. 3387-3395
Author(s):  
A.U. Wells ◽  
H.R. Branley
Keyword(s):  
High Resolution ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Vascular Disease ◽  
Pulmonary Vascular Disease ◽  
Systemic Diseases ◽  
High Resolution Ct ◽  
Significant Disease

Lung complications occur in all rheumatological disorders, but their frequency and type vary strikingly between different systemic diseases. Greater routine use of high-resolution CT and echocardiography means that interstitial lung disease and pulmonary vascular disease are increasingly recognized, which can create clinical difficulty in distinguishing between subclinical involvement and significant disease....

scholarly journals Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep

Respirology ◽  
2017 ◽  
Vol 22 (5) ◽  
pp. 1022-1034 ◽  
Author(s):  
Adelle S. Jee ◽  
Tamera J. Corte ◽  
Stephen J. Wort ◽  
Neil D. Eves ◽  
Claire E. Wainwright ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Interstitial Lung Disease ◽  
Pulmonary Function ◽  
Lung Disease ◽  
Vascular Disease ◽  
Pulmonary Vascular Disease ◽  
Paediatric Lung Disease

scholarly journals Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea

2020 ◽  
Vol 10 (1) ◽  
pp. 204589401989191 ◽  
Author(s):  
Richard H. Zou ◽  
William D. Wallace ◽  
S. Mehdi Nouraie ◽  
Stephen Y. Chan ◽  
Michael G. Risbano
Keyword(s):  
Pulmonary Hypertension ◽  
Lung Disease ◽  
Vascular Disease ◽  
Pulmonary Function Tests ◽  
Pulmonary Vascular Disease ◽  
Chronic Obstructive ◽  
Exertional Dyspnea ◽  
Pulmonary Arterial ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Exercise pulmonary hypertension is an underappreciated form of physical limitation related to early pulmonary vascular disease. A low diffusing capacity of lungs for carbon monoxide (DLco) can be seen in patients with resting pulmonary hypertension as well as parenchymal lung disease. It remains unclear whether low DLco% identifies early pulmonary vascular disease. We hypothesize that a reduced DLco% differentiates the presence of exercise pulmonary hypertension in patients with parenchymal lung disease. Fifty-six patients referred for unexplained exertional dyspnea with pulmonary function tests within six months of hemodynamic testing underwent exercise right heart catheterization. Exclusion criteria included resting pulmonary arterial or venous hypertension. Receiver operator characteristic curve determined the optimal DLco% cutoffs based on the presence or absence of parenchymal lung disease. Twenty-one (37%) patients had parenchymal lung disease, most common manifesting as chronic obstructive lung disease or interstitial lung disease. In patients with parenchymal lung disease, a DLco of 46% demonstrated 100% sensitivity and 73% specificity for detecting exercise pulmonary hypertension. In patients without parenchymal lung disease, a DLco of 73% demonstrated 58% sensitivity and 94% specificity for detecting exercise pulmonary hypertension. In both cohorts, DLco% below the optimum cutoffs were associated with higher peak mean pulmonary arterial pressure and peak total pulmonary resistance consistent with the hemodynamic definition of exercise pulmonary hypertension. Patients with a DLco < 46% were more often treated with pulmonary vasodilators and had a trend to higher mortality and lung transplant. DLco% is a simple non-invasive screening test for the presence of exercise pulmonary hypertension in our mixed referral population with progressive exertional dyspnea. DLco < 46% with parenchymal lung disease and DLco < 73% without parenchymal lung disease may play a role in differentiating the presence of pulmonary vascular disease prior to invasive hemodynamic testing.

Sign in / Sign up

Export Citation Format

Share Document